# Safety and Potential Effect of Innovative Cell-based Therapy Using Adipose-derived Stromal Vascular Fraction in Patients With Autoimmune Xerostomia

> **NCT05857358** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Assistance Publique Hopitaux De Marseille** · enrollment: 18 (estimated)

## Conditions studied

- Xerostomia

## Interventions

- **PROCEDURE:** lipoaspiration
- **DRUG:** Injection of the autologous adipose-derived stromal vascular fraction (AD-SVF)

## Key facts

- **NCT ID:** NCT05857358
- **Lead sponsor:** Assistance Publique Hopitaux De Marseille
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-01
- **Primary completion:** 2026-02
- **Final completion:** 2027-08
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05857358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05857358, "Safety and Potential Effect of Innovative Cell-based Therapy Using Adipose-derived Stromal Vascular Fraction in Patients With Autoimmune Xerostomia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05857358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*